Claims for Patent: 9,822,174

Summary for Patent: 9,822,174

Title:	Anti-VEGF antibody, and pharmaceutical composition for preventing, diagnosing or treating cancer or angiogenesis-related diseases, containing same
Abstract:	A novel anti-vascular endothelial growth factor (VEGF) antibody having a strong binding affinity for VEGF and capable of inhibiting in vivo tumor growth and a composition for the treatment of cancer, containing the same. The antibody shows a remarkable binding property to human and mouse VEGF, suppresses the proliferation and permeability of a human umbilical vein endothelial cell (HUVEC) and inhibits tumor growth, and thus can be useful as an antibody for the treatment of cancer.
Inventor(s):	Doh; Hyounmie (Seoul, KR), Kim; Byong Moon (Seoul, KR), Kim; Chae Young (Suwon-si, KR), Lee; Sung-Hee (Seoul, KR), Kim; Dong-Hyeon (Daejeon, KR), Kim; Yoo-jin (Yongin-si, KR), Lee; Dongsop (Yongin-si, KR), Han; Kyung Mi (Yongin-si, KR), Song; Dongsup (Suwon-si, KR), Jung; Eun-ee (Seoul, KR), Lee; Jinseok (Suwon-si, KR), Seung; Woo Jin (Seoul, KR), Hwang; Kyusang (Seoul, KR)
Assignee:	DONG-A SOCIO HOLDINGS CO., LTD. (Seoul, KR) DONG-A ST CO., LTD (Seoul, KR)
Application Number:	14/893,813
Patent Claims:	1. An antibody that binds to vascular endothelial growth factor (VEGF), the antibody comprising: 1) a light chain variable region comprising complementarity determining region (CDR)1, CDR2 and CDR3, wherein the CDR1 is represented by an amino acid sequence selected from the group consisting of SEQ ID NOs: 4-14; the CDR2 is represented by the amino acid sequence of SEQ ID NO: 1; and the CDR3 is represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1, CDR2 and CDR3, wherein the CDR1 is represented by an amino acid sequence selected from the group consisting of SEQ ID NOs: 15-34; the CDR 2 is represented an the amino acid sequence selected from the group consisting of SEQ ID NOs: 35-50; and the CDR3 is represented by the amino acid sequence of SEQ ID NO: 3, wherein the antibody is selected from the group consisting of: (i) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 4, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 15, CDR 2 represented by the amino acid sequence of SEQ ID NO: 35 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (ii) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 5, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 16, CDR 2 represented by the amino acid sequence of SEQ ID NO: 36 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (iii) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 5, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 17, CDR 2 represented by the amino acid sequence of SEQ ID NO: 37 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (iv) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 5, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 18, CDR 2 represented by the amino acid sequence of SEQ ID NO: 38 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (v) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 5, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 19, CDR 2 represented by the amino acid sequence of SEQ ID NO: 39 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (vi) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 5, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 20, CDR 2 represented by the amino acid sequence of SEQ ID NO: 40 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (vii) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 6, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 21, CDR 2 represented by the amino acid sequence of SEQ ID NO: 38 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (viii) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 6, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 22, CDR 2 represented by the amino acid sequence of SEQ ID NO: 38 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (ix) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 7, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 23, CDR 2 represented by the amino acid sequence of SEQ ID NO: 41 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (x) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 6, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 24, CDR 2 represented by the amino acid sequence of SEQ ID NO: 38 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xi) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 6, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 25, CDR 2 represented by the amino acid sequence of SEQ ID NO: 38 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xii) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 8, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 26, CDR 2 represented by the amino acid sequence of SEQ ID NO: 42 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xiii) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 6, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 27, CDR 2 represented by the amino acid sequence of SEQ ID NO: 38 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xiv) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 9, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 28, CDR 2 represented by the amino acid sequence of SEQ ID NO: 43 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xv) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 5, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 29, CDR 2 represented by the amino acid sequence of SEQ ID NO: 44 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xvi) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 10, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 30, CDR 2 represented by the amino acid sequence of SEQ ID NO: 45 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xvii) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 11, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 31, CDR 2 represented by the amino acid sequence of SEQ ID NO: 42 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xviii) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 11, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 20, CDR 2 represented by the amino acid sequence of SEQ ID NO: 39 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xix) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 11, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 32, CDR 2 represented by the amino acid sequence of SEQ ID NO: 46 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xx) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 5, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 33, CDR 2 represented by the amino acid sequence of SEQ ID NO: 45 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xxi) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 5, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 34, CDR 2 represented by the amino acid sequence of SEQ ID NO: 47 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xxii) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 6, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 25, CDR 2 represented by the amino acid sequence of SEQ ID NO: 48 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xxiii) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 12, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 31, CDR 2 represented by the amino acid sequence of SEQ ID NO: 38 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xxiv) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 9, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2 and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 31, CDR 2 represented by the amino acid sequence of SEQ ID NO: 46 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xxv) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 10, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 17, CDR 2 represented by the amino acid sequence of SEQ ID NO: 42 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; (xxvi) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 13, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 34, CDR 2 represented by the amino acid sequence of SEQ ID NO: 49 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3; and (xxvii) the antibody comprising 1) a light chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 14, CDR 2 represented by the amino acid sequence of SEQ ID NO: 1 and CDR3 represented by the amino acid sequence of SEQ ID NO: 2; and 2) a heavy chain variable region comprising CDR1 represented by the amino acid sequence of SEQ ID NO: 17, CDR 2 represented by the amino acid sequence of SEQ ID NO: 50 and CDR3 represented by the amino acid sequence of SEQ ID NO: 3. 2. An antibody that binds to vascular endothelial growth factor (VEGF), wherein the antibody is selected from the group consisting of: (i) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 54 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 78; (ii) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 55 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 79; (iii) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 55 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 80; (iv) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 56 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 81; (v) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 55 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 82; (vi) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 55 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 83; (vii) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 57 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 84; (viii) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 57 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 85; (ix) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 58 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 86; (x) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 57 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 87; (xi) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 57 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 88; (xii) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 59 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 89; (xiii) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 57 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 90; (xiv) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 60 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 91; (xv) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 55 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 92; (xvi) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 61 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 93; (xvii) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 62 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 94; (xviii) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 62 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 95; (xix) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 62 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 96; (xx) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 55 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 97; (xxi) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 55 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 98; (xxii) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 57 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 99; (xxiii) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 63 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 100; (xxiv) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 60 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 101; (xxv) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 61 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 102; (xxvi) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 64 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 103; and (xxvii) the antibody comprising 1) a light chain variable region represented by the amino acid sequence of SEQ ID NO: 65 and 2) a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 104. 3. The VEGF-binding antibody of claim 1, wherein the antibody is a human or humanized antibody. 4. The VEGF-binding antibody of claim 1, wherein the antibody is IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE or IgM. 5. The VEGF-binding antibody of claim 4, wherein the antibody is Fab, Fab', F(ab').sub.2, Fv, dAb, scFv or a scaffold conjugate which comprises the CDR of said antibody. 6. A pharmaceutical composition comprising the antibody according to claim 1. 7. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition further comprising a chemotherapeutic agent selected from a group consisting of an alkylating agent, an antimetabolite, a folic acid homologue, a pyrimidine homologue, a purine homologue and related inhibitor, a vinca alkaloid, an epipodophyllotoxin, antibiotics, L-asparaginase, a topoisomerase inhibitor, interferon, a platinum coordination complex, anthracenedione-substituted urea, a methyl hydrazine derivative, an adrenocortical suppressor, an adrenocorticosteroid, progestin, estrogen, antiestrogen, androgen, antiandrogen and gonadotropin-releasing hormone homologue. 8. The pharmaceutical composition of claim 6, wherein the pharmaceutical composition further comprising a drug selected from a group consisting of a fluoropyrimidine-based drug, paclitaxel, a platinum-based drug, interferon alpha-2a, carboplatin, doxorubicin, cisplatin, gemcitabine, 5-fluorouracil, leucovorin, irinotecan, oxalaplatin, capecitabine, docetaxel, and a mixture thereof. 9. A diagnostic kit for cancer or an angiogenesis-related disease caused by over-expression of VEGF, the kit comprising the antibody that binds to VEGF according to claim 1. 10. The VEGF-binding antibody of claim 2, wherein the antibody is a human or humanized antibody. 11. The VEGF-binding antibody of claim 2, wherein the antibody is IgG1, IgG2, IgG3, IgG4, IgA1, IgA2, IgD, IgE or IgM. 12. The VEGF-binding antibody of claim 11, wherein the antibody is Fab, Fab', F(ab').sub.2, Fv, dAb, scFv or a scaffold conjugate which comprises the CDR of said antibody. 13. A pharmaceutical composition comprising the antibody according to claim 2. 14. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition further comprising a chemotherapeutic agent selected from a group consisting of an alkylating agent, an antimetabolite, a folic acid homologue, a pyrimidine homologue, a purine homologue and related inhibitor, a vinca alkaloid, an epipodophyllotoxin, antibiotics, L-asparaginase, a topoisomerase inhibitor, interferon, a platinum coordination complex, anthracenedione-substituted urea, a methyl hydrazine derivative, an adrenocortical suppressor, an adrenocorticosteroid, progestin, estrogen, antiestrogen, androgen, antiandrogen and gonadotropin-releasing hormone homologue. 15. The pharmaceutical composition of claim 13, wherein the pharmaceutical composition further comprising a drug selected from a group consisting of a fluoropyrimidine-based drug, paclitaxel, a platinum-based drug, interferon alpha-2a, carboplatin, doxorubicin, cisplatin, gemcitabine, 5-fluorouracil, leucovorin, irinotecan, oxalaplatin, capecitabine, docetaxel, and a mixture thereof. 16. A diagnostic kit for cancer or an angiogenesis-related disease caused by over-expression of VEGF, the kit comprising the antibody that binds to VEGF according to claim 2.

Details for Patent 9,822,174

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2033-05-31